{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:50:55Z","timestamp":1791258655870,"version":"4.1.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05971-w","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:03:57Z","timestamp":1791255837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic drug transporters in pharmacotherapy: mechanisms, therapeutic targeting, and clinical translation"],"prefix":"10.1007","author":[{"given":"Abdul","family":"Shadab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"5971_CR1","doi-asserted-by":"publisher","first-page":"100132","DOI":"10.1016\/j.molpha.2026.100132","volume":"108","author":"V Aditya","year":"2026","unstructured":"Aditya V, Tambe V, Niyonshuti P, Kayesh R, Soderblom E, Zhang X, Xu C, Yue W (2026) Regulation of organic anion transporting polypeptide 1B1 transport function by lysine deacetylase 6. Mol Pharmacol 108:100132\u2013100132. https:\/\/doi.org\/10.1016\/j.molpha.2026.100132","journal-title":"Mol Pharmacol"},{"key":"5971_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2026.104173","author":"Y Ahn","year":"2026","unstructured":"Ahn Y, Brouwer K, Tiley JB (2026) Application of an in vitro model to elucidate liver disease-mediated alterations in the hepatic localization of organic anion transporting polypeptide (OATP)2B1 (Abstract ID: 225669). J Pharmacol Exp Ther. https:\/\/doi.org\/10.1016\/j.jpet.2026.104173","journal-title":"J Pharmacol Exp Ther"},{"key":"5971_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030855","author":"K Alam","year":"2018","unstructured":"Alam K, Crowe A, Wang X, Zhang P, Ding K, Li L, Yue W (2018) Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19030855","journal-title":"Int J Mol Sci"},{"key":"5971_CR4","doi-asserted-by":"publisher","unstructured":"Ali I, Slizgi J, Kaullen J, Ivanovi\u0107 M, Niemi M, Stewart P, Barritt A, Brouwer K (2018) Transporter\u2010mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate. Clin Pharmacol Ther\u00a0104. https:\/\/doi.org\/10.1002\/cpt.997","DOI":"10.1002\/cpt.997"},{"key":"5971_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/17425255.2022.2113380","volume":"18","author":"N Anabtawi","year":"2022","unstructured":"Anabtawi N, Drabison T, Hu S, Sparreboom A, Talebi Z (2022) The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature. Expert Opin Drug Metab Toxicol 18:459\u2013468. https:\/\/doi.org\/10.1080\/17425255.2022.2113380","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5971_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115681","volume":"214","author":"M Asensio","year":"2023","unstructured":"Asensio M, Herr\u00e1ez E, Mac\u00edas R, Lozano E, Mu\u00f1oz-Bellv\u00eds L, Sanchez-Vicente L, Morente-Carrasco A, Marin J, Briz O (2023) Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma. Biochem Pharmacol 115681. https:\/\/doi.org\/10.1016\/j.bcp.2023.115681","journal-title":"Biochem Pharmacol"},{"key":"5971_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2026.111217","author":"D Barber","year":"2026","unstructured":"Barber D, Naughton F, Van Hilten N, Grabe M, Paz A (2026) A conserved salt bridge network stabilizes the hepatic organic anion transporters OATP1B1 and OATP1B3. J Biol Chem. https:\/\/doi.org\/10.1016\/j.jbc.2026.111217","journal-title":"J Biol Chem"},{"key":"5971_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/164_2021_448","author":"R Betterton","year":"2021","unstructured":"Betterton R, Davis T, Ronaldson P (2021) Organic cation transporter (OCT\/OCTN) expression at brain barrier sites: focus on CNS drug delivery. Handb Exp Pharmacol. https:\/\/doi.org\/10.1007\/164_2021_448","journal-title":"Handb Exp Pharmacol"},{"key":"5971_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/jpet.119.257600","volume":"370","author":"Y Bi","year":"2019","unstructured":"Bi Y, Costales C, Mathialagan S, West M, Eatemadpour S, Lazzaro S, Tylaska L, Scialis R, Zhang H, Umland J, Kimoto E, Tess D, Feng B, Tremaine L, Varma M, Rodrigues A (2019) Quantitative contribution of six major transporters to the hepatic uptake of drugs: \u201cSLC-Phenotyping\u201d using primary human hepatocytes. J Pharmacol Exp Ther 370:72\u201383. https:\/\/doi.org\/10.1124\/jpet.119.257600","journal-title":"J Pharmacol Exp Ther"},{"key":"5971_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1124\/dmd.123.001630","volume":"52","author":"Y Bi","year":"2024","unstructured":"Bi Y, Jordan S, King-Ahmad A, West M, Yamaguchi E, Ryu S, Mathialagan S, Tess D, Varma M (2024) Low molecular weight acids and organic anion transporting polypeptide (OATP1B)-mediated hepatic clearance: in vitro and in vivo evaluation using novel hypoxia-inducible factor prolyl hydroxylase inhibitors (Dustats). Drug Metab Dispos 52:399\u2013407. https:\/\/doi.org\/10.1124\/dmd.123.001630","journal-title":"Drug Metab Dispos"},{"key":"5971_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1124\/dmd.117.077289","volume":"46","author":"S Billington","year":"2018","unstructured":"Billington S, Ray A, Salphati L, Xiao G, Chu X, Humphreys W, Liao M, Lee C, Mathias A, Hop C, Rowbottom C, Evers R, Lai Y, Kelly E, Prasad B, Unadkat J (2018) Transporter expression in noncancerous and cancerous liver tissue from donors with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS\/MS proteomics. Drug Metab Dispos 46:189\u2013196. https:\/\/doi.org\/10.1124\/dmd.117.077289","journal-title":"Drug Metab Dispos"},{"key":"5971_CR13","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1080\/03639045.2026.2676198","volume":"52","author":"X Cao","year":"2026","unstructured":"Cao X, Yang Y, Adu-Frimpong M, Chen H, Yuan L, Berdiyar J, Yu J, Wang Q, Xu X (2026) Leveraging bile acid transporters for enhanced liver targeting and anti-alcoholic efficacy of tectoridin via liposomal delivery. Drug Dev Ind Pharm 52:1516\u20131530. https:\/\/doi.org\/10.1080\/03639045.2026.2676198","journal-title":"Drug Dev Ind Pharm"},{"key":"5971_CR14","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.2147\/ijn.s415968","volume":"18","author":"T Caputo","year":"2023","unstructured":"Caputo T, Cusano A, Principe S, Cicatiello P, Celetti G, Aliberti A, Micco A, Ruvo M, Tagliamonte M, Ragone C, Minopoli M, Carriero M, Buonaguro L, Cusano A (2023) Sorafenib-loaded PLGA carriers for enhanced drug delivery and cellular uptake in liver cancer cells. Int J Nanomedicine 18:4121\u20134142. https:\/\/doi.org\/10.2147\/ijn.s415968","journal-title":"Int J Nanomedicine"},{"key":"5971_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2025.1550723","author":"H Chen","year":"2025","unstructured":"Chen H (2025) Roles of organic anion transporting polypeptides in hepatocellular carcinoma. Front Genet. https:\/\/doi.org\/10.3389\/fgene.2025.1550723","journal-title":"Front Genet"},{"key":"5971_CR16","doi-asserted-by":"publisher","DOI":"10.1039\/d2bm00316c","author":"A Chowdhury","year":"2022","unstructured":"Chowdhury A, Bai RG, Islam T, Abir M, Narayan M, Khatun Z, Nurunnabi M (2022) Bile acid linked \u03b2-glucan nanoparticles for liver specific oral delivery of biologics. Biomater Sci. https:\/\/doi.org\/10.1039\/d2bm00316c","journal-title":"Biomater Sci"},{"issue":"10","key":"5971_CR17","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1021\/acs.molpharmaceut.3c01245","volume":"21","author":"J Cui","year":"2024","unstructured":"Cui J, Wen Z, Huang H, Qin S, Luo Y, Zhang W, Wu W (2024) The pharmacokinetics and liver-targeting evaluation of silybin liposomes mediated by the NTCP\/OCTN2 dual receptors. Mol Pharm 21(10):4912\u20134923. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c01245","journal-title":"Mol Pharm"},{"key":"5971_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.70394","author":"J Dong","year":"2026","unstructured":"Dong J, Zhong J, Wang X, Geng D, Mao C, Chen Z, Lu T (2026) In vivo evidence of human organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 mediated disposition of glycyrrhizin and its drug-drug interactions in humanized mice. Phytother Res. https:\/\/doi.org\/10.1002\/ptr.70394","journal-title":"Phytother Res"},{"key":"5971_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22083821","author":"A-M Enge","year":"2021","unstructured":"Enge A-M, Kaltner F, Gottschalk C, Braeuning A, Hessel-Pras S (2021a) Active transport of hepatotoxic pyrrolizidine alkaloids in HepaRG cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22083821","journal-title":"Int J Mol Sci"},{"key":"5971_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202100800","author":"A-M Enge","year":"2021","unstructured":"Enge A-M, Kaltner F, Gottschalk C, Kin A, Kirstgen M, Geyer J, These A, Hammer H, P\u00f6tz O, Braeuning A, Hessel-Pras S (2021) Organic cation transporter I and Na+ \/taurocholate co-transporting polypeptide are involved in retrorsine- and senecionine-induced hepatotoxicity in HepaRG cells. Mol Nutr Food Res. https:\/\/doi.org\/10.1002\/mnfr.202100800","journal-title":"Mol Nutr Food Res"},{"key":"5971_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.18433\/jpps31818","volume":"24","author":"T Farasyn","year":"2021","unstructured":"Farasyn T, Xu C, Yue W (2021) Development of a rat sandwich-cultured hepatocytes model expressing functional human organic anion transporting polypeptide (OATP) 1B3: a potential screening tool for liver-targeting compounds. J Pharm Pharm Sci 24:475\u2013483. https:\/\/doi.org\/10.18433\/jpps31818","journal-title":"J Pharm Pharm Sci"},{"key":"5971_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1124\/dmd.124.001792","volume":"52","author":"B Feng","year":"2024","unstructured":"Feng B, Liang G, Zetterberg C, Li S, Huang H, Williams J, Gao H, Morikawa Y, Kumar S (2024) Utility of chimeric mice with humanized livers for predicting hepatic organic anion-transporting polypeptide 1B\u2013mediated clinical drug-drug interactions. Drug Metab Dispos 52:1073\u20131082. https:\/\/doi.org\/10.1124\/dmd.124.001792","journal-title":"Drug Metab Dispos"},{"key":"5971_CR25","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1177\/24725552211017500","volume":"26","author":"S Floerl","year":"2021","unstructured":"Floerl S, Kuehne A, Geyer J, Brockmoeller J, Tzvetkov M, Hagos Y (2021) Functional and pharmacological comparison of human and mouse Na+\/taurocholate cotransporting polypeptide (NTCP). SLAS Discov 26:1055\u20131064. https:\/\/doi.org\/10.1177\/24725552211017500","journal-title":"SLAS Discov"},{"key":"5971_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1517\/17425255.4.4.363","volume":"4","author":"C Funk","year":"2008","unstructured":"Funk C (2008) The role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol 4:363\u2013379. https:\/\/doi.org\/10.1517\/17425255.4.4.363","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5971_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","volume":"23","author":"A Galetin","year":"2024","unstructured":"Galetin A, Brouwer K, Tweedie D, Yoshida K, Sj\u00f6stedt N, Aleksunes L, Chu X, Evers R, Hafey M, Lai Y, Matsson P, Riselli A, Shen H, Sparreboom A, Varma M, Yang J, Yang X, Yee S, Zamek-Gliszczynski M, Brouwer KLR, Hafey MJ, Varma MVS, Yee SW, Zamek-Gliszczynski MJ, Zhang L, Giacomini KM, Giacomini K (2024) Membrane transporters in drug development and as determinants of precision medicine. Nat Rev Drug Discov 23:255\u2013280. https:\/\/doi.org\/10.1038\/s41573-023-00877-1","journal-title":"Nat Rev Drug Discov"},{"key":"5971_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering12111206","author":"Y Gao","year":"2025","unstructured":"Gao Y, Wang J-P, Hong D, Yang C, Naranmandura H (2025) Mesenchymal stem cell-mediated targeted drug delivery systems for hepatocellular carcinoma: current advances and future directions. Bioengineering. https:\/\/doi.org\/10.3390\/bioengineering12111206","journal-title":"Bioengineering"},{"key":"5971_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202007727","author":"Y Guan","year":"2021","unstructured":"Guan Y, Yao W, Yi K, Zheng C, Lv S, Tao Y, Hei Z, Li M (2021) Nanotheranostics for the management of hepatic ischemia-reperfusion injury. Small. https:\/\/doi.org\/10.1002\/smll.202007727","journal-title":"Small"},{"key":"5971_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040448","author":"X Guo","year":"2025","unstructured":"Guo X, Liu Z, Wu L, Guo P (2025) Preparation and evaluation of hepatoma-targeting glycyrrhetinic acid composite micelles loaded with curcumin. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph18040448","journal-title":"Pharmaceuticals (Basel)"},{"key":"5971_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.662535","author":"B Haberkorn","year":"2021","unstructured":"Haberkorn B, Fromm M, K\u00f6nig J (2021) Transport of drugs and endogenous compounds mediated by human OCT1: studies in single- and double-transfected cell models. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.662535","journal-title":"Front Pharmacol"},{"issue":"2","key":"5971_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2024.100023","volume":"77","author":"B Hagenbuch","year":"2024","unstructured":"Hagenbuch B, Stieger B, Locher K (2024) Organic anion transporting polypeptides: pharmacology, toxicology, structure, and transport mechanisms. Pharmacol Rev 77(2):100023. https:\/\/doi.org\/10.1016\/j.pharmr.2024.100023","journal-title":"Pharmacol Rev"},{"key":"5971_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02214-x","author":"J He","year":"2025","unstructured":"He J, Yu H, Song K, Huang A-L, Dang Y, Chen J, Guo Z (2025) Rapavir, a novel inhibitor of sodium taurocholate cotransporting polypeptide, potently blocks hepatitis B virus entry. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-025-02214-x","journal-title":"Signal Transduct Target Ther"},{"key":"5971_CR34","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1124\/dmd.124.001708","volume":"52","author":"P Hegde","year":"2024","unstructured":"Hegde P, Morse B (2024) Mechanistic account of distinct change in organic anion transporting polypeptide 1B (OATP1B) substrate pharmacokinetics during OATP1B-mediated drug-drug interactions using physiologically based pharmacokinetic modeling. Drug Metab Dispos 52:886\u2013898. https:\/\/doi.org\/10.1124\/dmd.124.001708","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"5971_CR36","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","volume":"130","author":"R Ho","year":"2006","unstructured":"Ho R, Tirona R, Leake B, Glaeser H, Lee W, Lemke C, Wang Y, Kim R (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130(6):1793\u20131806. https:\/\/doi.org\/10.1053\/j.gastro.2006.02.034","journal-title":"Gastroenterology"},{"issue":"7","key":"5971_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2026.100339","volume":"54","author":"C Hu","year":"2026","unstructured":"Hu C, Wang R, Tirona R, Schwarz U (2026) Role of organic anion transporting polypeptides in pancreatic statin disposition and islet cell function in mice. Drug Metab Dispos Biol Fate Chem 54(7):100339. https:\/\/doi.org\/10.1016\/j.dmd.2026.100339","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"5971_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158457","author":"J Idowu","year":"2022","unstructured":"Idowu J, Hagenbuch B (2022) Free cholesterol affects the function and localization of human Na+\/taurocholate cotransporting polypeptide (NTCP) and organic cation transporter 1 (OCT1). Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23158457","journal-title":"Int J Mol Sci"},{"key":"5971_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/livers5030045","author":"J Idowu","year":"2025","unstructured":"Idowu J, McKimens C, Hagenbuch B (2025) Effects of chronic elevation in plasma membrane cholesterol on the function of human Na+\/taurocholate cotransporting polypeptide (NTCP) and organic cation transporter 1 (OCT1). Livers. https:\/\/doi.org\/10.3390\/livers5030045","journal-title":"Livers"},{"key":"5971_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.802539","author":"E J\u00e4rvinen","year":"2022","unstructured":"J\u00e4rvinen E, Deng F, Kiander W, Sinokki A, Kidron H, Sj\u00f6stedt N (2022) The role of uptake and efflux transporters in the disposition of glucuronide and sulfate conjugates. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.802539","journal-title":"Front Pharmacol"},{"key":"5971_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.04.018","author":"A Jetter","year":"2020","unstructured":"Jetter A, Kullak-Ublick G (2020) Drugs and hepatic transporters: a review. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2019.04.018","journal-title":"Pharmacol Res"},{"key":"5971_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/dmd.120.000125","volume":"49","author":"R Jiang","year":"2020","unstructured":"Jiang R, Hart A, Burgess L, Kim D-S, Lai W, Dixit V (2020) Prediction of transporter-mediated drug-drug interactions and phenotyping of hepatobiliary transporters involved in the clearance of E7766, a novel macrocycle-bridged dinucleotide. Drug Metab Dispos 49:265\u2013275. https:\/\/doi.org\/10.1124\/dmd.120.000125","journal-title":"Drug Metab Dispos"},{"key":"5971_CR45","doi-asserted-by":"publisher","unstructured":"Kaci H, Bakos \u00c9, Needs P, Kroon P, Valentov\u00e1 K, Po\u00f3r M, \u00d6zvegy\u2010Laczka C (2024) The 2-aminoethyl diphenylborinate-based fluorescent method identifies quercetin and luteolin metabolites as substrates of organic anion transporting polypeptides, OATP1B1 and OATP2B1. Eur J Pharm Sci: Off J Eur Fed Pharm Sci\u00a0106740. https:\/\/doi.org\/10.1016\/j.ejps.2024.106740","DOI":"10.1016\/j.ejps.2024.106740"},{"key":"5971_CR46","doi-asserted-by":"publisher","unstructured":"Kumar V, Xin X, Jingyi Tan C, Osna N, Mahato R (2021) Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev\u00a0113888. https:\/\/doi.org\/10.1016\/j.addr.2021.113888","DOI":"10.1016\/j.addr.2021.113888"},{"key":"5971_CR47","doi-asserted-by":"publisher","unstructured":"Kurobe-Takashima Y, Yanagisawa K, Saito Y, Miyawaki R, Misaka T, Mizoi J, Miyauchi E, Sasaki N, Ogihara T, Kobayashi S (2026) Contribution of organic anion transporting polypeptides to bile acid uptake in the Caco-2 cell monolayer and gastrointestinal tract. J Biol Chem 302. https:\/\/doi.org\/10.1016\/j.jbc.2026.111205","DOI":"10.1016\/j.jbc.2026.111205"},{"key":"5971_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1124\/jpet.123.001754","volume":"387","author":"L Lash","year":"2023","unstructured":"Lash L (2023) A novel approach to predicting organic anion transporting polypeptide function in human hepatic drug disposition and biliary clearance. J Pharmacol Exp Ther 387:131\u2013134. https:\/\/doi.org\/10.1124\/jpet.123.001754","journal-title":"J Pharmacol Exp Ther"},{"key":"5971_CR49","doi-asserted-by":"publisher","unstructured":"Li Y, Zhou J, Li T (2022) Regulation of the HBV entry receptor NTCP and its potential in hepatitis B treatment. Front Mol Biosci\u00a09. https:\/\/doi.org\/10.3389\/fmolb.2022.879817","DOI":"10.3389\/fmolb.2022.879817"},{"key":"5971_CR50","doi-asserted-by":"publisher","unstructured":"Li W, Iusuf D, Sparidans R, Wagenaar E, Wang Y, de Waart D, Martins M, van Hoppe S, Lebre M, van Tellingen O, Beijnen J, Schinkel A (2023) Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs. Pharm Res\u00a0106724. https:\/\/doi.org\/10.1016\/j.phrs.2023.106724","DOI":"10.1016\/j.phrs.2023.106724"},{"key":"5971_CR51","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.2147\/dddt.s480151","volume":"18","author":"S Li","year":"2024","unstructured":"Li S, Hao L, Deng J, Zhang J, Yu F, Ye F, Li N, Hu X (2024) The culprit behind HBV-infected hepatocytes: NTCP. Drug des Devel Ther 18:4839\u20134858. https:\/\/doi.org\/10.2147\/dddt.s480151","journal-title":"Drug des Devel Ther"},{"issue":"7","key":"5971_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100101","volume":"53","author":"Y Li","year":"2025","unstructured":"Li Y, Yabut J, Zhang Z, Fauty S, Houle R, Miller H, Zhang NR, Shin M, Rosahl T, Zhou H, Prasad B, Unadkat J, Chu X (2025) Characterization of organic anion transporting polypeptide (OATP)1B1 and OATP1B3 humanized rat as a translational model to study the pharmacokinetics of OATP1B substrate drugs. Drug Metab Dispos 53(7):100101. https:\/\/doi.org\/10.1016\/j.dmd.2025.100101","journal-title":"Drug Metab Dispos"},{"key":"5971_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134748","author":"T Liang","year":"2024","unstructured":"Liang T, Liu H, Li L, Huan R, Gui C (2024) Human organic anion transporting polypeptide 1B3 (OATP1B3) is more heavily N-glycosylated than OATP1B1 in extracellular loops 2 and 5. Int J Biol Macromol. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.134748","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"5971_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2026.100242","volume":"54","author":"T Liang","year":"2026","unstructured":"Liang T, Dong Y, Huan R, Chen S, Zhang C, Yang L, Jiang J, Gui C (2026) Importance of extracellular disulfide bonds for the surface expression and function of human organic anion transporting polypeptide 1B1. Drug Metab Dispos Biol Fate Chem 54(3):100242. https:\/\/doi.org\/10.1016\/j.dmd.2026.100242","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"5971_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12645-022-00139-6","volume":"13","author":"J Ling","year":"2022","unstructured":"Ling J, Jiang Y, Yan S, Dang H, Yue H, Liu K, Kuang L, Liu X, Tang H (2022) A novel pH- and glutathione-responsive drug delivery system based on in situ growth of MOF199 on mesoporous organic silica nanoparticles targeting the hepatocellular carcinoma niche. Cancer Nanotechnology 13:1\u201321. https:\/\/doi.org\/10.1186\/s12645-022-00139-6","journal-title":"Cancer Nanotechnology"},{"key":"5971_CR56","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1080\/10717544.2021.2021324","volume":"29","author":"X Liu","year":"2021","unstructured":"Liu X, Wu Z, Guo C, Guo H, Su Y, Chen Q, Sun C, Liu Q, Chen D, Mu H (2021) Hypoxia responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy. Drug Delivery 29:138\u2013148. https:\/\/doi.org\/10.1080\/10717544.2021.2021324","journal-title":"Drug Delivery"},{"key":"5971_CR57","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c01205","author":"N Loos","year":"2024","unstructured":"Loos N, Martins MF, Rijmers J, de Jong D, Lebre M, Tibben M, Beijnen J, Schinkel A (2024) Interplay of ritonavir-boosted oral cabazitaxel with the organic anion-transporting polypeptide (OATP) uptake transporters and carboxylesterase 1 in mice. Mol Pharm. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c01205","journal-title":"Mol Pharm"},{"key":"5971_CR58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","volume":"6","author":"M Manzari","year":"2021","unstructured":"Manzari M, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller D (2021) Targeted drug delivery strategies for precision medicines. Nat Rev Mater 6:351\u2013370. https:\/\/doi.org\/10.1038\/s41578-020-00269-6","journal-title":"Nat Rev Mater"},{"key":"5971_CR59","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00984","author":"L Martinez-Guerrero","year":"2025","unstructured":"Martinez-Guerrero L, Vignaux P, Harris J, Lane T, Urbina F, Wright S, Ekins S, Cherrington N (2025) Computational approaches for predicting drug interactions with human organic anion transporter 4 (OAT4). Mol Pharm. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00984","journal-title":"Mol Pharm"},{"key":"5971_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2026.100381","author":"S Mathialagan","year":"2026","unstructured":"Mathialagan S, Yee S, Orozco CC, Gernhardt S, Yamaguchi E, West MA, Sannino S, Phillips TB, Sommese R, Tess DA, Varma M (2026) Cyclosporine A, macrocyclic peptide, is transported by organic anion transporting-polypeptide 1B1\/1B3 at clinically relevant doses. Drug Metab Dispos. https:\/\/doi.org\/10.1016\/j.dmd.2026.100381","journal-title":"Drug Metab Dispos"},{"key":"5971_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.713567","author":"S Medwid","year":"2021","unstructured":"Medwid S, Price H, Taylor D, Mailloux J, Schwarz U, Kim R, Tirona R (2021) Organic anion transporting polypeptide 2B1 (OATP2B1) genetic variants: in vitro functional characterization and association with circulating concentrations of endogenous substrates. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.713567","journal-title":"Front Pharmacol"},{"key":"5971_CR62","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02605-9","author":"M Nasr","year":"2023","unstructured":"Nasr M, Kira A, Saber S, Essa E, El-Gizawy S (2023) Telmisartan-loaded lactosylated chitosan nanoparticles as a liver specific delivery system: synthesis, optimization and targeting efficiency. AAPS PharmSciTech. https:\/\/doi.org\/10.1208\/s12249-023-02605-9","journal-title":"AAPS PharmSciTech"},{"key":"5971_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jcmgh.2023.04.007","volume":"16","author":"Q-J Pan","year":"2023","unstructured":"Pan Q-J, Zhu G, Xu Z, Zhu J, Ouyang J, Tong Y-J, Zhao N, Zhang X, Cheng Y, Zhang L, Tan Y, Li J, Zhang C, Chen W-S, Cai S-Y, Boyer J, Chai J (2023) Organic anion transporting polypeptide (OATP) 1B3 is a significant transporter for hepatic uptake of conjugated bile acids in humans. Cell Mol Gastroenterol Hepatol 16:223\u2013242. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.04.007","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"5971_CR64","doi-asserted-by":"publisher","unstructured":"Pan J, Wang Y, Chen Y, Zhang C, Deng H, Lu J, Chen W (2025) Emerging strategies against accelerated blood clearance phenomenon of nanocarrier drug delivery systems. J Nanobiotechnol\u00a023. https:\/\/doi.org\/10.1186\/s12951-025-03209-0","DOI":"10.1186\/s12951-025-03209-0"},{"issue":"11","key":"5971_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100172","volume":"53","author":"J Pan","year":"2025","unstructured":"Pan J, Zhang C, Lu H, Zhang X, Deng H, Chen Y, Wang L, Zhang S, Wang F, Chen W (2025) Activation of pregnane X receptor-organic anion transporting polypeptide 1a\/b \/P-glycoprotein\/multidrug resistance protein 2 axis mediates the accelerated blood and liver clearance of PEGylated liposomes. Drug Metab Dispos 53(11):100172. https:\/\/doi.org\/10.1016\/j.dmd.2025.100172","journal-title":"Drug Metab Dispos"},{"key":"5971_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020364","author":"E Puris","year":"2023","unstructured":"Puris E, Fricker G, Gynther M (2023) The role of solute carrier transporters in efficient anticancer drug delivery and therapy. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15020364","journal-title":"Pharmaceutics"},{"key":"5971_CR67","doi-asserted-by":"publisher","unstructured":"Raza M, Sinokki A, Monnonen M, Neuvonen M, Niemi M, Sj\u00f6stedt N, Kidron H (2026) In vitro inhibition of organic anion transporting polypeptide 2B1 (OATP2B1) is common among marketed drugs. Eur J Pharm Sci: Off J Eur Fed Pharm Sci 107492. https:\/\/doi.org\/10.1016\/j.ejps.2026.107492","DOI":"10.1016\/j.ejps.2026.107492"},{"key":"5971_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2026.178853","volume":"1022","author":"L Ren","year":"2026","unstructured":"Ren L, Wang D, He Y, Wu X, Zhu W, Yin Y, Lin Y, Yu X, Su Z, Wu Y (2026) Regulation of OATP1B1 and OATP1B3 by HNF3\u03b1 and\/or c-Jun mediates rosuvastatin hepatic uptake. Eur J Pharmacol 1022:178853. https:\/\/doi.org\/10.1016\/j.ejphar.2026.178853","journal-title":"Eur J Pharmacol"},{"key":"5971_CR69","doi-asserted-by":"publisher","unstructured":"Sabit H, Pawlik T, Radwan F, Abdel-Hakeem M, Abdel-Ghany S, Wadan A-H S, Elzawahri M, El-Hashash A, Arneth B (2025) Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol Cancer\u00a024. https:\/\/doi.org\/10.1186\/s12943-025-02357-z","DOI":"10.1186\/s12943-025-02357-z"},{"key":"5971_CR70","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/gutjnl-2020-323345","volume":"71","author":"A Salhab","year":"2021","unstructured":"Salhab A, Amer J, Lu Y, Safadi R (2021) Sodium+\/taurocholate cotransporting polypeptide as target therapy for liver fibrosis. Gut 71:1373\u20131385. https:\/\/doi.org\/10.1136\/gutjnl-2020-323345","journal-title":"Gut"},{"key":"5971_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/s12247-026-10876-5","volume":"22","author":"A Shadab","year":"2027","unstructured":"Shadab A, Haider MF, Abohassan M (2027) Lipid nanoparticles based drug delivery systems: design innovations, therapeutic applications, and translational progress. J Pharm Innov 22:2. https:\/\/doi.org\/10.1007\/s12247-026-10876-5","journal-title":"J Pharm Innov"},{"key":"5971_CR72","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41422-023-00870-8","volume":"33","author":"Z Shan","year":"2023","unstructured":"Shan Z, Yang X, Liu H, Yuan Y, Xiao Y, Nan J, Zhang W, Song W, Wang J, Wei F, Zhang Y (2023) Cryo-EM structures of human organic anion transporting polypeptide OATP1B1. Cell Res 33:940\u2013951. https:\/\/doi.org\/10.1038\/s41422-023-00870-8","journal-title":"Cell Res"},{"key":"5971_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2024.100246","author":"B Shen","year":"2024","unstructured":"Shen B, Zhu Y, Wang F, Deng X, Yue P, Yuan H, Shen C (2024) Fabrication and in vitro\/vivo evaluation of quercetin nanocrystals stabilized by glycyrrhizic acid for liver targeted drug delivery. International Journal of Pharmaceutics: X. https:\/\/doi.org\/10.1016\/j.ijpx.2024.100246","journal-title":"Int J Pharm: X"},{"key":"5971_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020784","author":"M Sohail","year":"2021","unstructured":"Sohail M, D\u00f6nmez-Cakil Y, Sz\u00f6ll\u0151si D, Stockner T, Chiba P (2021) The bile salt export pump: molecular structure, study models and small-molecule drugs for the treatment of inherited BSEP deficiencies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22020784","journal-title":"Int J Mol Sci"},{"key":"5971_CR75","doi-asserted-by":"publisher","first-page":"17781","DOI":"10.1039\/d4ra07489k","volume":"15","author":"J Song","year":"2025","unstructured":"Song J, Zhang H, Zhang X, Liu M, Peng D, Ren Y, Sun Y, Li Y (2025) Galactose-modified erythrocyte membrane fusion liposomes enable the targeted delivery of drug nanoparticles to the liver. RSC Adv 15:17781\u201317794. https:\/\/doi.org\/10.1039\/d4ra07489k","journal-title":"RSC Adv"},{"key":"5971_CR76","doi-asserted-by":"publisher","unstructured":"Stoll F, Seidel-Gl\u00e4tzer A, Burghaus I, G\u00f6ring O, Sauter M, Rose P, Daniel V, Haag M, Schwab M, Riffel J, Andr\u00e9 F, Taylor L, Weiss J, Burhenne J, Cleeves V, Haefeli W, Blank A (2022) Metabolic effect of blocking sodium-taurocholate co-transporting polypeptide in hypercholesterolemic humans with a twelve-week course of bulevirtide\u2014an exploratory phase I clinical trial. Int J Mol Sci\u00a023. https:\/\/doi.org\/10.3390\/ijms232415924","DOI":"10.3390\/ijms232415924"},{"key":"5971_CR77","doi-asserted-by":"publisher","DOI":"10.1111\/febs.17255","author":"D Surrer","year":"2024","unstructured":"Surrer D, Sch\u00fcsser S, K\u00f6nig J, Fromm M, Gessner A (2024) Transport of aromatic amino acids l\u2010tryptophan, l\u2010tyrosine, and l\u2010phenylalanine by the organic anion transporting polypeptide (OATP) 3A1. FEBS J. https:\/\/doi.org\/10.1111\/febs.17255","journal-title":"FEBS J"},{"key":"5971_CR79","doi-asserted-by":"publisher","first-page":"100246","DOI":"10.1016\/j.dmd.2026.100246","volume":"54","author":"V Tambe","year":"2026","unstructured":"Tambe V, Niyonshuti P, Aditya V, Hays FA, Kayesh R, Soderblom E, Xu C, Yue W (2026) Post-translational regulation of organic anion transporting polypeptide 1B3 transport function by lysine acetylation and lysine deacetylase 6 inhibition. Drug Metab Dispos 54:100246\u2013100246. https:\/\/doi.org\/10.1016\/j.dmd.2026.100246","journal-title":"Drug Metab Dispos"},{"key":"5971_CR80","doi-asserted-by":"publisher","unstructured":"Tan X, Xiang Y, Shi J, Chen L, Yu D (2024) Targeting NTCP for liver disease treatment: a promising strategy. J Pharm Anal\u00a014. https:\/\/doi.org\/10.1016\/j.jpha.2024.100979","DOI":"10.1016\/j.jpha.2024.100979"},{"key":"5971_CR81","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c02158","author":"R Tang","year":"2021","unstructured":"Tang R, Li R, Li H, Du X, Yu P, Ren X, Wang L-L, Zheng W-S (2021) Design of hepatic targeted drug delivery systems for natural products: insights into nomenclature revision of nonalcoholic fatty liver disease. ACS Nano. https:\/\/doi.org\/10.1021\/acsnano.1c02158","journal-title":"ACS Nano"},{"issue":"2","key":"5971_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2026.184509","volume":"1868","author":"M Tanino","year":"2026","unstructured":"Tanino M, Tsujii K, Kataoka H, Takahashi R, Imaoka A, Akiyoshi T, Ohtani H (2026) Effects of N-glycosylation on the transport kinetics of organic anion transporting polypeptide (OATP) 1B1. Biochimica et Biophysica Acta (BBA) - Biomembranes 184509. https:\/\/doi.org\/10.1016\/j.bbamem.2026.184509","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"key":"5971_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73636-w","author":"G Tassone","year":"2024","unstructured":"Tassone G, Maramai S, Paolino M, Lamponi S, Poggialini F, Dreassi E, Petricci E, Alcaro S, Pozzi C, Romeo I (2024) Exploiting the bile acid binding protein as transporter of a cholic acid\/mirin bioconjugate for potential applications in liver cancer therapy. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-024-73636-w","journal-title":"Sci Rep"},{"key":"5971_CR84","doi-asserted-by":"publisher","first-page":"15094","DOI":"10.1021\/acs.jmedchem.3c01026","volume":"66","author":"A Tonduru","year":"2023","unstructured":"Tonduru A, Maljaei SH, Adla S, Anamea L, Tampio J, Kr\u00e1lov\u00e1 A, Jalkanen A, Espada C, Santos IF, Montaser A, Rautio J, Kronenberger T, Poso A, Huttunen K (2023) Targeting glial cells by organic anion-transporting polypeptide 1C1 (OATP1C1)-utilizing L-thyroxine-derived prodrugs. J Med Chem 66:15094\u201315114. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01026","journal-title":"J Med Chem"},{"issue":"7","key":"5971_CR85","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2174\/1568026611313070008","volume":"13","author":"M Tu","year":"2013","unstructured":"Tu M, Mathiowetz A, Pfefferkorn J, Cameron K, Dow R, Litchfield J, Di L, Feng B, Liras S (2013) Medicinal chemistry design principles for liver targeting through OATP transporters. Curr Top Med Chem 13(7):857\u2013866. https:\/\/doi.org\/10.2174\/1568026611313070008","journal-title":"Curr Top Med Chem"},{"key":"5971_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124381","author":"J Unagolla","year":"2024","unstructured":"Unagolla J, Das S, Flanagan R, Oehler M, Menon J (2024) Targeting chronic liver diseases: molecular markers, drug delivery strategies and future perspectives. Int J Pharm. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124381","journal-title":"Int J Pharm"},{"key":"5971_CR87","doi-asserted-by":"publisher","unstructured":"Ungv\u00e1ri O, Kir\u00e1ly L, Bakos \u00c9, \u00d6zvegy\u2010Laczka C (2021) 8\u2010acetoxy\u2010trisulfopyrene as the first activatable fluorogenic probe for add\u2010and\u2010read assessment of organic anion\u2010transporting polypeptides, OATP1B1, OATP1B3, and OATP2B1. FASEB J\u00a035. https:\/\/doi.org\/10.1096\/fj.202100648r","DOI":"10.1096\/fj.202100648r"},{"key":"5971_CR88","doi-asserted-by":"publisher","unstructured":"Ungv\u00e1ri O, Bakos \u00c9, Kovacsics D, \u00d6zvegy\u2010Laczka C (2023) The fluorescence\u2010based competitive counterflow assay developed for organic anion transporting polypeptides 1A2, 1B1, 1B3 and 2B1 identifies pentamidine as a selective OATP1A2 substrate. FASEB J\u00a037. https:\/\/doi.org\/10.1096\/fj.202300530rr","DOI":"10.1096\/fj.202300530rr"},{"issue":"7","key":"5971_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2026.100330","volume":"54","author":"CE Villanueva","year":"2026","unstructured":"Villanueva CE, Nolte WM, Flores-Ascencio P, Hagenbuch B (2026) Loss of palmitoylation impacts the interaction between the organic anion transporting polypeptide (OATP) 1B1 and OATP1B3. Drug Metab Dispos 54(7):100330. https:\/\/doi.org\/10.1016\/j.dmd.2026.100330","journal-title":"Drug Metab Dispos"},{"key":"5971_CR90","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1124\/dmd.116.071050","volume":"44","author":"L Wang","year":"2016","unstructured":"Wang L, Collins C, Kelly E, Chu X, Ray A, Salphati L, Xiao G, Lee C, Lai Y, Liao M, Mathias A, Evers R, Humphreys W, Hop C, Kumer S, Unadkat J (2016) Transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis quantified by targeted quantitative proteomics. Drug Metab Dispos 44:1752\u20131758. https:\/\/doi.org\/10.1124\/dmd.116.071050","journal-title":"Drug Metab Dispos"},{"key":"5971_CR91","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2022","unstructured":"Wang X, Liu S, Sun Y, Yu X, Lee S, Cheng Q, Wei T, Gong J, Robinson J, Zhang D, Lian X, Basak P, Siegwart D (2022) Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc 18:265\u2013291. https:\/\/doi.org\/10.1038\/s41596-022-00755-x","journal-title":"Nat Protoc"},{"key":"5971_CR92","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c11453","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang Z, Zhang Z, Zou Z, Zhuo Y, Liu C, Nie D, Gan Y, Yu M (2024) Enhanced gut-to-liver oral drug delivery via ligand-modified nanoparticles by attenuating protein corona adsorption. ACS Nano. https:\/\/doi.org\/10.1021\/acsnano.4c11453","journal-title":"ACS Nano"},{"key":"5971_CR93","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1016\/j.apsb.2025.04.003","volume":"15","author":"Q Wang","year":"2025","unstructured":"Wang Q, Wan B, Feng Y, Yang Z, Li D, Liu F, Gao Y, Li C, Liu Y, Sun Y, He Z, Luo C, Sun J, Jiang Q (2025) Self-degradable \u201cgemini-like\u201d ionizable lipid-mediated delivery of siRNA for subcellular-specific gene therapy of hepatic diseases. Acta Pharm Sin B 15:2867\u20132883. https:\/\/doi.org\/10.1016\/j.apsb.2025.04.003","journal-title":"Acta Pharm Sin B"},{"key":"5971_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052525","author":"J Wei","year":"2024","unstructured":"Wei J, Tan Y, Bai Y, He J, Cao H, Guo J, Su Z (2024) Mesoporous silicon nanoparticles with liver-targeting and pH-response-release function are used for targeted drug delivery in liver cancer treatment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25052525","journal-title":"Int J Mol Sci"},{"key":"5971_CR95","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1161\/strokeaha.123.043649","volume":"54","author":"E Williams","year":"2023","unstructured":"Williams E, Betterton R, Stanton J, Moreno-Rodriguez V, Lochhead J, Davis T, Ronaldson P (2023) Oatp (organic anion transporting polypeptide)-mediated transport: a mechanism for atorvastatin neuroprotection in stroke. Stroke 54:2875\u20132885. https:\/\/doi.org\/10.1161\/strokeaha.123.043649","journal-title":"Stroke"},{"key":"5971_CR96","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.42276","volume":"8","author":"D Witzigmann","year":"2019","unstructured":"Witzigmann D, Uhl P, Sieber S, Kaufman C, Einfalt T, Sch\u00f6neweis K, Grossen P, Buck J, Ni Y, Schenk SH, Hussner J, Meyer zu Schwabedissen HE, Qu\u00e9batte G, Mier W, Urban S, Huwyler J (2019a) Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide. eLife 8:e42276. https:\/\/doi.org\/10.7554\/eLife.42276","journal-title":"eLife"},{"key":"5971_CR97","doi-asserted-by":"publisher","unstructured":"Witzigmann D, Uhl P, Sieber S, Kaufman C, Einfalt T, Sch\u00f6neweis K, Grossen P, Buck J, Ni Y, Schenk S, Hussner J, Schwabedissen HMZ, Qu\u00e9batte G, Mier W, Urban S, Huwyler J (2019) Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide. eLife\u00a08. https:\/\/doi.org\/10.7554\/elife.42276","DOI":"10.7554\/elife.42276"},{"key":"5971_CR98","doi-asserted-by":"publisher","unstructured":"Xiao H, Zheng Y, Lingling Tian L, Sun Q (2021) Clinically-relevant ABC transporter for anti-cancer drug resistance. Front Pharmacol\u00a012. https:\/\/doi.org\/10.3389\/fphar.2021.648407","DOI":"10.3389\/fphar.2021.648407"},{"issue":"3","key":"5971_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2026.104664","volume":"31","author":"Q Xie","year":"2026","unstructured":"Xie Q, Liu Q, Zheng X, Fu L, Aly HH, Liu B (2026) Sodium taurocholate cotransporting polypeptide in HBV-related diseases: from underlying mechanisms to targeted therapies. Drug Discov Today 31(3):104664. https:\/\/doi.org\/10.1016\/j.drudis.2026.104664","journal-title":"Drug Discov Today"},{"key":"5971_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1496498","author":"J Xu","year":"2025","unstructured":"Xu J, Liu Y (2025) Nanomaterials for liver cancer targeting: research progress and future prospects. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1496498","journal-title":"Front Immunol"},{"key":"5971_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158508","author":"M Yamauchi","year":"2022","unstructured":"Yamauchi M, Sato T, Otake A, Kumondai M, Sato Y, Kikuchi M, Maekawa M, Yamaguchi H, Abe T, Mano N (2022) Bile acid\u2013drug interaction via organic anion-transporting polypeptide 4C1 is a potential mechanism of altered pharmacokinetics of renally excreted drugs. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23158508","journal-title":"Int J Mol Sci"},{"key":"5971_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2025.117266","author":"F Yang","year":"2025","unstructured":"Yang F, Wu L, Xu W, Wu Y, Zhu S, Zhang Y, Chong Y, Peng L (2025) Sodium taurocholate co-transporting polypeptide deficiency attenuates acetaminophen-induced hepatotoxicity via regulating expression of drug metabolism enzymes in mice. Toxicol Appl Pharmacol. https:\/\/doi.org\/10.1016\/j.taap.2025.117266","journal-title":"Toxicol Appl Pharmacol"},{"key":"5971_CR103","doi-asserted-by":"publisher","unstructured":"Yanrong Mu J, Gou X, Wu X (2025) Precision medication based on the evaluation of drug metabolizing enzyme and transporter functions. Precis Clin Med\u00a08. https:\/\/doi.org\/10.1093\/pcmedi\/pbaf004","DOI":"10.1093\/pcmedi\/pbaf004"},{"key":"5971_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010196","author":"D Zakrzewicz","year":"2022","unstructured":"Zakrzewicz D, Geyer J (2022) Multitasking Na+\/taurocholate cotransporting polypeptide (NTCP) as a drug target for HBV infection: from protein engineering to drug discovery. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10010196","journal-title":"Biomedicines"},{"key":"5971_CR105","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1515\/hsz-2022-0345","volume":"404","author":"D Zakrzewicz","year":"2023","unstructured":"Zakrzewicz D, Geyer J (2023) Interactions of Na+\/taurocholate cotransporting polypeptide with host cellular proteins upon hepatitis B and D virus infection: novel potential targets for antiviral therapy. Biol Chem 404:673\u2013690. https:\/\/doi.org\/10.1515\/hsz-2022-0345","journal-title":"Biol Chem"},{"key":"5971_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/v14061259","author":"D Zakrzewicz","year":"2022","unstructured":"Zakrzewicz D, Leidolf R, Kunz S, M\u00fcller S, Neubauer A, Leiting S, Goldmann N, Lehmann F, Glebe D, Geyer J (2022) Tyrosine 146 of the human Na+\/taurocholate cotransporting polypeptide (NTCP) is essential for its hepatitis B virus (HBV) receptor function and HBV entry into hepatocytes. Viruses. https:\/\/doi.org\/10.3390\/v14061259","journal-title":"Viruses"},{"key":"5971_CR107","doi-asserted-by":"publisher","unstructured":"Zerdoug A, V\u00e9e L, Uehara S, Jamin A, Higuchi Y, Yoneda N, Lopez B, Chesn\u00e9 C, Suemizu H, Fardel O (2023) Drug transporter expression and activity in cryopreserved human hepatocytes isolated from chimeric TK-NOG mice with humanized livers. Toxicol in Vitro\u202f\u00a0105592. https:\/\/doi.org\/10.1016\/j.tiv.2023.105592","DOI":"10.1016\/j.tiv.2023.105592"},{"issue":"6","key":"5971_CR108","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1021\/acs.molpharmaceut.8b01226","volume":"16","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Panfen E, Fancher M, Sinz M, Marathe P, Shen H (2019) Dissecting the contribution of OATP1B1 to hepatic uptake of statins using the OATP1B1 selective inhibitor estropipate. Mol Pharm 16(6):2342\u20132353. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b01226","journal-title":"Mol Pharm"},{"key":"5971_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115956","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang Q, Zhang Y, Lou Y, Ge L, Zhang W, Zhang W, Song F, Huang P (2023) Role of sodium taurocholate cotransporting polypeptide (NTCP) in HBV-induced hepatitis: opportunities for developing novel therapeutics. Biochem Pharmacol. https:\/\/doi.org\/10.1016\/j.bcp.2023.115956","journal-title":"Biochem Pharmacol"},{"key":"5971_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/livers1040019","author":"X Zhao","year":"2021","unstructured":"Zhao X, Iqbal W, Sun P, Zhou X (2021) Na+-taurocholate co-transporting polypeptide (NTCP) in livers, function, expression regulation, and potential in hepatitis B treatment. Livers. https:\/\/doi.org\/10.3390\/livers1040019","journal-title":"Livers"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05971-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05971-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05971-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:04:02Z","timestamp":1791255842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05971-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":103,"alternative-id":["5971"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05971-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"4 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares that Grammarly was used solely for language editing, grammar correction, and improvement of sentence clarity. No AI-based tools were used to generate scientific content, interpret results, or alter the scientific meaning of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}